Axiogenesis Overview
- Founded
- 2000
- Status
- Acquired/Merged
- Employees
- 32
- Latest Deal Type
- M&A
Axiogenesis General Information
Description
Producer of stem cell-based assays that enable drug development. The company's stem cell-based assays engage in production and use of transgenic and physiologically relevant tissues and cells derived from induced pluripotent stem cells and embryonic stem cells in drug development, enabling drug development enterprises to accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
- Nattermannallee 1, Building S20
- 50829 Cologne
- Germany
Axiogenesis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 18-Sep-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 03-May-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 05-Jun-2012 | Completed | Generating Revenue | |||
| 3. PIPE | 23-Mar-2011 | Completed | Generating Revenue | |||
| 2. IPO | 19-Dec-2007 | Completed | Generating Revenue | |||
| 1. Later Stage VC | Completed | Generating Revenue |
Axiogenesis Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Producer of stem cell-based assays that enable drug development. The company's stem cell-based assays engage in producti
Biotechnology
Cologne, Germany
32
As of 2016
000000&0
00000000
m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000 000000000
Cambridge, United Kingdom
00
As of 0000
00.000
0000000000
00.000
00000000
ute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exc
0000000000000
Beit-Haemek, Israel
000
As of 0000
0000
000
0000-00-00
000000&0
0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAxiogenesis Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DefiniGEN | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00.000 | 0000000000 | 00.000 |
| 0000000000 0000000 | Formerly PE-Backed | Beit-Haemek, Israel | 000 | 0000 | 000000&0 | 0000 |
| 000 0000000000000 | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000000 00000000 | Formerly VC-backed | Madison, WI | 000 | 00000 | 000000&0 | 00000 |
| 000000000 | Formerly VC-backed | Yokohama, Japan | 000 | 000.00 | 00000000 | 000.00 |
Axiogenesis Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Michelle Stevens | Director, Business Development | ||
| Brian Murphy | Director, Marketing & Sales | ||
| Heribert Bohlen Ph.D | Co-Founder & Chief Executive Officer |
Axiogenesis Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAxiogenesis Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Donghai Securities | Holding Company | Minority | 000 0000 | 000000 0 | |
| High-Tech Gründerfonds | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Venture Plus | Venture Capital | Minority | 000 0000 | 000000 0 |